Clinical trial · Observational
Discordant HER2/Neu Status of Breast Cancer.
Discordant HER2/Neu Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.
NCT01935739CI-TRIAL-00012108completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine discordant HER2/neu status of primary breast tumor and metastatic breast cancer cells at regional lymph nodes in node positive breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm of Breast. | Malignant Breast Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Primary Breast Tumor
- description
- Primary breast tumor were test for HER2/neu status.
- label
- Axillary Lymph Nodes.
- description
- Axillary Lymph Nodes were tested for HER2/neu status.
Primary outcomes (1)
- measure
- Association of HER2/neu status between primary breast tumor and axillary lymph nodes
- timeFrame
- up to 1 year
- description
- Association of HER2/neu status between primary breast tumor and axillary lymph nodes was analyzed by using the χ2 test
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer patients stage I,II and III with axillary lymph nodes metastasis. Exclusion Criteria: * Breast cancer patients stage I,II and III without axillary lymph nodes metastasis.
References
Publications (2)
- BACKGROUNDCristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91. doi: 10.1056/NEJMoa040766. PMID 15317891
- BACKGROUNDCristofanilli M. The biological information obtainable from circulating tumor cells. Breast. 2009 Oct;18 Suppl 3:S38-40. doi: 10.1016/S0960-9776(09)70270-X. PMID 19914540